Sildenafil
Product Images NDC 17224-460

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 17224-460). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Calvin, Scott And Company, Incorporated, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (Label)

Label (Label)
FDA Label Image

Figure-10 (Sildenafil Fig 10)

Figure-10 (Sildenafil Fig 10)
FDA Label Image

Figure-11 (Sildenafil Fig 11)

Figure-11 (Sildenafil Fig 11)
FDA Label Image

Fig-12 (Sildenafil Fig 12)

Fig-12 (Sildenafil Fig 12)
FDA Label Image

Fig-6 (Sildenafil Fig 6)

Fig-6 (Sildenafil Fig 6)
FDA Label Image

Fig-8 (Sildenafil Fig 8)

Fig-8 (Sildenafil Fig 8)
This appears to be a chart or table providing information on the recommended fold change and 90% confidence interval (CI) for various drugs with respect to their interaction with other drugs. It also includes guidelines for dose adjustment and potential effects on exercise capacity or bleeding time. The drugs listed include Conocoumarol, Aspirin, Atorvastatin, Bosentan, Doxazosin, Ethinyloestradiol, Lovonorgestrel, Phenpr, Ritonavir, Saquinavir, and Tolbutamide.*
FDA Label Image

Figure-9 (Sildenafil Fig 9)

Figure-9 (Sildenafil Fig 9)
FDA Label Image

Figure-7 (Sildenafil Figure 7)

Figure-7 (Sildenafil Figure 7)
This is a table that summarizes the drug interaction with Sildenafil. It shows the fold change in drug interaction and recommends whether a dose adjustment is needed or not. Several drugs including Atorasttn, Astromycn UG, Bosentan, Cimetidine, Evermyel:f, beoanod c and Saquinavie do not require dose adjustment. However, oral contraceptives are not recommended for co-administration with Sildenafil. It also mentions that there is no benefit on exercise capacity when sildenafil is added to bosentan therapy. A graph is also provided showing the relative change in AUC accumulation ratio from Day 1 to Day 7 of Sildenafil alone with a vertical solid line at x=1.*
FDA Label Image

Str (Sildenafil Str)

Str (Sildenafil Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.